NDAORALTABLET
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
IBRANCE (palbociclib) by Pfizer is kinase inhibitors [moa]. Approved for breast cancer. First approved in 2019.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IBRANCE (palbociclib) is an oral small-molecule CDK4/6 kinase inhibitor approved in 2019 for multiple cancer types including breast cancer, renal cell carcinoma, pancreatic cancer, and advanced solid tumors. It works by inhibiting cyclin-dependent kinases 4 and 6, which are key regulators of cell cycle progression in tumor cells. The drug is indicated across 15 cancer types, making it a broadly applicable oncology franchise.
$2.0BPart D
Peak10.8 years to LOEIBRANCE is in peak commercial phase with $2.0B in annual spending, indicating a well-resourced brand team with stable market presence and mature infrastructure.
Mechanism of Action
Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications (1)
Clinical Trials (20)
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Started Nov 2025
25 enrolled
Metastatic Renal Cell CarcinomaMetastatic Renal CancerRenal Cell Carcinoma+3 more
A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database
Started Jun 2025
1 enrolled
Advanced or Metastatic Breast Cancer
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Started Feb 2025
54 enrolled
Well Differentiated LiposarcomaDedifferentiated LiposarcomaLiposarcoma+6 more
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
Started Jan 2025
1,772 enrolled
Breast Neoplasms
A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)
Started Aug 2024
733 enrolled
Breast Cancer
Worked on IBRANCE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.